KPVvsVilon

KPV is a tripeptide (Lys-Pro-Val) derived from the C-terminal end of alpha-melanocyte stimulating hormone (α-MSH), specifically residues 11-13. While the full α-MSH molecule exerts anti-inflammatory effects primarily through melanocortin receptor activation (particularly MC1R), KPV achieves its anti-inflammatory activity through a distinct, receptor-independent mechanism that does not produce the tanning or sexual side effects associated with melanocortin receptor activation.

KPV's primary mechanism is direct inhibition of the NF-κB inflammatory signaling pathway. It enters cells (possibly through peptide transporters or direct membrane penetration due to its small size) and interacts with the IKK complex (IκB kinase), preventing the phosphorylation and subsequent proteasomal degradation of IκBα. When IκBα remains intact, it sequesters the NF-κB transcription factor (p65/p50 dimer) in the cytoplasm, preventing its nuclear translocation. This blocks transcription of a wide array of pro-inflammatory genes including TNF-α, IL-1β, IL-6, IL-8, COX-2, and iNOS — effectively shutting down the inflammatory cascade at a master regulatory level.

This mechanism makes KPV particularly interesting for inflammatory conditions of the gut and skin, where NF-κB activation drives chronic inflammation. In intestinal epithelial cells, KPV reduces inflammatory cytokine production and may help restore barrier function in conditions like inflammatory bowel disease (IBD). Topically, it suppresses cutaneous inflammation in models of contact dermatitis and psoriasis. The oral bioavailability of KPV — unusual for peptides — is attributed to its small size (only 3 amino acids) and resistance to gastrointestinal proteases, allowing it to reach the intestinal epithelium intact when taken orally. This clean anti-inflammatory profile without melanocortin receptor side effects makes KPV a focused anti-inflammatory tool.

Vilon (Lys-Glu) is a synthetic dipeptide bioregulator developed as part of the Khavinson peptide bioregulator program, designed to mimic the immune-regulatory effects of thymic peptides in the shortest possible amino acid sequence. As a dipeptide, it is one of the smallest molecules proposed to have specific gene-regulatory activity — which is both its appeal (simplicity, stability, oral bioavailability) and the source of scientific skepticism (whether a two-amino-acid molecule can have specific transcriptional effects).

Vilon is proposed to regulate thymic function and T-cell immunity through the peptide bioregulator mechanism: penetrating cell membranes, entering the nucleus, and interacting with specific DNA sequences in immune-related gene promoters. The reported effects include enhanced T-cell differentiation from thymic precursors, improved balance between CD4+ helper and CD8+ cytotoxic T cell populations, and modulation of cytokine production toward a more balanced Th1/Th2 immune profile.

Preclinical and clinical studies from the Khavinson group have reported that Vilon treatment enhances immune surveillance (the ability of the immune system to detect and eliminate abnormal cells), improves vaccine responsiveness in elderly subjects, and partially reverses age-related immunosenescence markers. In combination with Epithalon (another Khavinson bioregulator targeting telomerase and the pineal gland), Vilon was reported to reduce mortality in a long-term follow-up study of elderly subjects in St. Petersburg. The proposed mechanism for immune enhancement involves restoration of thymic peptide signaling that declines with age-related thymic involution, essentially providing a minimal molecular signal that tells immune progenitor cells to differentiate and mature. As with all Khavinson bioregulators, independent validation through Western clinical trial standards is still needed.